NCT01503736 - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease | Biotech Hunter

Enrollment

183

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2012

Conditions

HyperphosphatemiaEnd Stage Renal DiseaseESRD

Interventions

DRUG

ferric citrate

0g/day ferric citrate capsule, TID for 56 days

DRUG

ferric citrate

4g/day ferric citrate capsule, TID for 56 days

DRUG

ferric citrate

6 g/day ferric citrate capsule, TID for 56 days

Trial Locations (5)

Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung City

Division of Nephrology, Keelung Chang Gung Memorial Hospital, Keelung

Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital, New Taipei City

Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung

Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei